Bone metastases from lung cancer can be treated with deslumizumab, but the therapeutic effect is still affected by a variety of factors, and the specific efficacy varies from person to person, so it is impossible to say how effective it is. Deslizumab is a kind of targeted drug for cancer treatment, which is suitable for patients with bone metastasis of solid tumors to delay or reduce the risk of bone-related events (e.g. pathological fracture, spinal cord compression, etc.). Therefore, lung cancer bone metastases can be treated with this drug. However, it should be noted that the therapeutic effect after the use of deslumizumab may be affected by various factors such as the physical condition of the patient, the timing of and compliance with treatment, the severity of bone metastasis, etc., and the specific therapeutic efficacy may be subject to individual differences, so it is not possible to predict the therapeutic efficacy of the treatment for a specific patient after the use of the drug. In addition, it should also be noted that Dixumab is contraindicated in hypersensitivity to the drug, or the presence of hypocalcemia, dental or oral surgery wounds have not yet healed, etc., headache, diarrhea, rash and other adverse reactions may occur in the process of using the drug. Therefore, people with bone metastases of lung cancer who have the demand for disulphatumab treatment must standardize the use of the drug under the guidance of doctors, and must not blindly use or increase or decrease the dosage of the drug on their own, so as to avoid inappropriate interventions and adverse consequences.